8-K: Evolent Health Reaches Cooperation Agreement with Engaged Capital, Appoints Brendan Springstubb to Board

Evolent Health and Engaged Capital enter into a cooperation agreement, resulting in the appointment of Brendan Springstubb to Evolent's Board of Directors and other governance changes.

Summary

• Evolent Health, Inc. has entered into a cooperation agreement with Engaged Capital, LLC, effective February 3, 2025.
• Brendan Springstubb has been appointed to Evolent's Board of Directors with a term expiring at the 2025 annual meeting of stockholders.
• Springstubb will also join the Strategy Committee immediately and either the Audit or Compensation Committee by the 2025 Annual Meeting.
• Engaged Capital, which beneficially owns approximately 4.8% of Evolent's common stock (5,619,468 shares), is subject to a standstill agreement, limiting its ability to acquire more than 9.9% of the company's voting securities.
• Engaged Capital agrees to vote its shares in favor of the Board's recommendations, with exceptions for Extraordinary Transactions and situations where ISS or Glass Lewis recommend otherwise.
• M. Bridget Duffy, MD, has resigned from the Board, and the vesting of her 7,709 restricted stock units has been accelerated.
• Richard Jelinek will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott.
• Evolent will reimburse Engaged Capital for up to $80,000 in expenses related to the agreement.
• The agreement terminates 30 days prior to the nomination deadline for the 2026 Annual Meeting, 30 days prior to the first anniversary of the 2025 Annual Meeting nomination deadline, or upon the closing of an Extraordinary Transaction.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The agreement with Engaged Capital is presented as a collaborative effort to enhance corporate governance and shareholder value. The appointment of a new director and the planned change in board leadership are viewed favorably. However, the standstill agreement and potential conflicts of interest introduce some caution.

Positives

• The agreement resolves potential conflicts and aligns the interests of Evolent and one of its major shareholders.
• The addition of Brendan Springstubb brings relevant experience to the Board.
• The Board refreshment and rotation of the Chair role demonstrate a commitment to corporate governance.
• Glenn W. Welling, Founder and CIO of Engaged Capital, expressed confidence in Evolent's ability to create value for shareholders.

Negatives

• The standstill agreement limits Engaged Capital's ability to increase its stake in Evolent.
• Springstubb's prior consulting relationship with Engaged Capital and potential future payments could raise conflict-of-interest concerns, although the Board has determined he is independent.
• The agreement could be perceived as giving Engaged Capital undue influence over Evolent's Board and strategy.

Risks

• Failure to comply with the terms of the cooperation agreement could lead to legal action.
• Changes in control or sale of assets could trigger termination of the agreement.
• Forward-looking statements regarding future performance are subject to risks and uncertainties.
• The market may react negatively to the perception of Engaged Capital's influence on the company.

Future Outlook

Evolent aims to continue its board refreshment efforts and leverage its competitive position to create value for shareholders, focusing on better health outcomes for people with complex conditions.

Management Comments

• Cheryl Scott stated that the Board refreshment builds on actions previously taken to ensure best-in-class corporate governance.
• Cheryl Scott expressed pleasure in deepening the capital markets and finance experience on the Board with Brendan's appointment.
• Glenn W. Welling believes Brendan will be a strong shareholder advocate in the Evolent boardroom.
• Seth Blackley stated that Rick and Brendan will be critical to ensuring value creation for all stakeholders.

Industry Context

Activist investors like Engaged Capital often seek board representation and governance changes to influence company strategy and improve shareholder value. This agreement reflects a trend of companies engaging with activist investors to reach mutually agreeable solutions.

Comparison to Industry Standards

• Cooperation agreements are a common tool used by companies and activist investors to avoid proxy fights and align interests.
• The standstill provisions are typical in such agreements, limiting the activist's ability to acquire additional shares or launch a proxy contest.
• The board refreshment process and appointment of independent directors are consistent with corporate governance best practices.
• Comparable companies that have entered into similar agreements include those targeted by other activist funds like Starboard Value, Elliott Management, and D.E. Shaw.

Management Changes

Legal Proceedings

• Each party agrees not to institute any lawsuit against the other party, subject to certain exceptions including the seeking of remedies for a breach of the Cooperation Agreement.

Related Party Transactions

• Mr. Springstubb was previously an employee of Engaged Capital and, until January 31, 2025, provided consulting services to Engaged Capital in connection with its investment in the Company and another publicly-traded healthcare company.
• As compensation for such services, Mr. Springstubb remains entitled to potential future contingent payments from Engaged Capital based on Engaged Capitals investment in the Company, consisting of (A) a success fee based on certain profits earned by Engaged Capitals clients since January 1, 2023 in relation to investment in the Company through full disposition of such investment less the total losses incurred by Engaged Capitals clients in connection with its investments in both the Company and another publicly-traded healthcare company through full disposition of such investments and (B) a $250,000 supplemental fee payable no later than twelve months following Engaged Capitals full disposition of its investment in the Company.
• Mr. Springstubb is an investor in certain funds managed by Engaged Capital that hold shares of the Companys Class A common stock.

Stakeholder Impact

• Shareholders: The agreement aims to enhance shareholder value through improved corporate governance and strategic alignment.
• Employees: The changes in board composition and leadership could influence company strategy and operations, potentially impacting employees.
• Customers: The focus on better health outcomes for people with complex conditions is expected to continue, benefiting customers.
• Suppliers: The agreement is unlikely to have a direct impact on suppliers.
• Creditors: The agreement is unlikely to have a direct impact on creditors.

Next Steps

• Richard Jelinek will be named Chair of the Board at the 2025 Annual Meeting.
• Brendan Springstubb will be appointed to either the Audit or Compensation Committee by the 2025 Annual Meeting.
• The Board intends to refresh an independent director seat in advance of the 2025 Annual Meeting.
• Engaged Capital will vote its shares in accordance with the agreement.

Key Dates

Keywords

Evolent Health, Engaged Capital, Cooperation Agreement, Board of Directors, Brendan Springstubb, Richard Jelinek, Corporate Governance, Shareholder Agreement, Standstill Agreement